A Phase 2, Single-Dose, Open-Label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies, in Patients Undergoing Routine Surgery
Latest Information Update: 13 Jul 2023
At a glance
- Drugs Pegsitacianine (Primary)
- Indications Lung cancer
- Focus Diagnostic use
- Sponsors OncoNano Medicine
- 17 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Apr 2022 Planned End Date changed from 1 Jul 2022 to 1 Oct 2022.